Search clinical trials for: BI 207127 NA (TF-II)

Total 137 results

Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Healthy

United States
Boehringer Ingelheim

Completed

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

Hepatitis C, Chronic
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Boehringer Ingelheim

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Hepatitis C, Chronic

United States, Australia, Austria, France, Germany, New Zealand, Portugal, Romania, Spain, Switzerland
Boehringer Ingelheim

Completed

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Boehringer Ingelheim

Terminated

Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients

Renal Insufficiency

Germany
Boehringer Ingelheim

Terminated

Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

Healthy

Germany
Presidio Pharmaceuticals, Inc.
Boehringer Ingelheim

Completed

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

United States
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Boehringer Ingelheim

Completed

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

Healthy

Germany
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
Boehringer Ingelheim

Terminated

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
The University of Tennessee, Knoxville

Completed

In Vivo Kinematics for Subjects With Smith & Nephew Journey II BCS TKA, Journey II CR TKA, Or Journey II XR TKA

Knee Osteoarthritis | Total Knee Arthroplasty | Knee

United States
Asahi Kasei Pharma Corporation

Recruiting

Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
The University of Tennessee, Knoxville
Smith & Nephew, Inc.

Completed

Kinematics in Posterior Cruciate Retaining and Bi-Cruciate Retaining Total Knee Replacements

Osteoarthritis, Knee | Arthroplasty, Replacement, Knee

United States
Boehringer Ingelheim

Completed

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

Healthy
BioGaia AB

Completed

Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women

Functional Constipation

Sweden
Boehringer Ingelheim

Completed

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Healthy
VU University of Amsterdam
Yoba for Life Foundation

Unknown

A Nutritional Trial on Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda

Skin Diseases | Respiratory Tract Infections | Diarrhea

Uganda
Boehringer Ingelheim

Terminated

Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel

Healthy

Germany
Boehringer Ingelheim

Completed

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)

Healthy

Germany
Boehringer Ingelheim

Completed

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

Healthy

United States
Boehringer Ingelheim

Recruiting

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Obesity | Overweight

Germany
Boehringer Ingelheim

Recruiting

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms

United States, Spain, Germany, Japan
Boehringer Ingelheim

Active, not recruiting

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Liposarcoma, Dedifferentiated

United States, Spain, Canada, Taiwan, Belgium, Australia, China, Italy, Germany, Japan, Hong Kong, Finland, United Kingdom, Denmark, France, Sweden, Netherlands, Portugal, Czechia, Greece, Norway
VU University of Amsterdam
Yoba for Life Foundation

Completed

Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda

Skin Diseases | Respiratory Tract Infections | Diarrhea | Common Cold | Tinea Capitis

Uganda
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities

Healthy

United Kingdom
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Small Cell Lung Cancer Extensive Stage

China
Boehringer Ingelheim

Recruiting

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (DAREONᵀᴹ-8)

Small Cell Lung Carcinoma (SCLC)

Spain, Belgium, Japan, France, Poland, Germany
Boehringer Ingelheim

Completed

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Hepatitis C, Chronic

United States, Canada, Germany
Tan Tock Seng Hospital
Melbourne Health; National University Hospital, Singapore; Samsung Medical Center and other collaborators

Recruiting

Early Oral Step-down Antibiotic Therapy for Uncomplicated Gram-negative Bacteraemia

Gram-negative Bacteraemia

Singapore
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer Recurrent

China
Boehringer Ingelheim

Completed

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Healthy

3

Subscribe